*0011185107
*008130612s2013    xx#           000 0 nob
*019  $bk
*08230$a615.1
*100  $aDale, Ola$4aut$_131262300
*245  $aKlinisk utprøvning – bare for industrien?
*300  $aS. 1043
*650  $aklinisk farmasi$9nor$2norart$_134274900
*650  $alegemidler$9nor$2norart$_128631500
*773  $tTidsskrift for Den norske legeforening$gÅrg. 133, nr. 10 (2013)$x0029-2001$w(NO-LaBS)552783(tnr)
*8564 $uhttps://doi.org/10.4045/tidsskr.13.0492
*999  $z1300538399$anorart:1300538399
^